Reduced Changes In Bone Mineral Density In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared With Tenofovir disoproxil fumarate

被引：0
|
作者：
Seto, Wai-Kay [2 ]
Asahina, Yasuhiro [3 ]
Peng, Cheng-Yuan [4 ]
Stanciu, Carol [5 ]
Abdurakhmanov, Djamal [6 ]
Flaherty, John F. [1 ]
Kim, Kyungpil [1 ]
Gaggar, Anuj [1 ]
Subramanian, Mani [1 ]
Tabak, Fehmi [7 ]
Nguyen, Tuan T. [8 ]
Chan, Henry Lik-Yuen [9 ]
机构：
[1] Gilead Sci, Foster City, CA USA
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Tokyo Med & Dent Univ, Gastroenterol & Hepatol, Tokyo, Japan
[4] China Med Univ Hosp, Div Hepatogastroenterol, Dept Internal Med, Taichung, Taiwan
[5] Univ Med & Pharm Gr T Popa, Inst Gastroenterol & Hepatol, Iasi, Romania
[6] Univ Clin Hosp 1, Moscow, Russia
[7] Istanbul Univ, Cerrahpassa Tip Fak Hastanesi, Infect Dis, Istanbul, Turkey
[8] Res & Educ Inc, San Diego, CA USA
[9] Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
67
引用
收藏
页码：35A / 35A
页数：1
相关论文
共 50 条
  • [1] Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF)
    Chuang, Wan-Long
    Seto, Wai-Kay
    Inokuma, Tetsuro
    Ikeda, Fusao
    Santantonio, Teresa A.
    Flaherty, John F.
    Kim, Kyungpil
    Gaggar, Anuj
    Subramanian, Mani
    Habersetzer, Francois
    Ramji, Alnoor
    Mukewar, Shrikant
    Chan, Henry Lik-Yuen
    Brunetto, Mau-rizia R.
    HEPATOLOGY, 2016, 64 : 916A - 917A
  • [2] Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir alafenamide (TAF) compared with Tenofovir Disoproxil Fumarate (TDF)
    Lim, Young-Suk
    Ide, Tatsuya
    Strasser, Simone I.
    Yoon, Ki Tae
    Paik, Seung Woon
    Flaherty, John F.
    Kim, Kyungpil
    Gaggar, Anuj
    Subramanian, Mani
    Mangia, Alessandra
    Simon, Krzysztof
    Kwan, Peter
    Gane, Edward J.
    HEPATOLOGY, 2016, 64 : 940A - 940A
  • [3] Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks
    Chuang, W. L.
    Agarwal, K.
    Hwang, J. S.
    Caruntu, F.
    Wong, F.
    Hann, H. W.
    Flaherty, J.
    Lau, A.
    Gaggar, A.
    Suri, V.
    Mo, S.
    Subramanian, G. M.
    Hui, A. J.
    Yatsuhashi, H.
    Lim, Y. S.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S695 - S695
  • [4] Characterization Of Changes In FibroTest Values During Treatment With Tenofovir Alfenamide (TAF) Or tenofovir disproxil fumarate (TDF) In Patients With CHB
    Izumi, Namiki
    Tsang, Owen Tak Yin
    Ahn, Sang Hoon
    Gurel, Selim
    Angus, Peter W.
    Flaherty, John F.
    Kim, Kyungpil
    Gaggar, Anuj
    Suri, Vithika
    Subramanian, Mani
    Cooper, Curtis
    Hann, Hie-Won
    Acharya, Subrat K.
    HEPATOLOGY, 2016, 64 : 941A - 942A
  • [5] Improved Renal Laboratory Parameters In CHB Patients Treated With TAF Compared With Tenofovir Disoproxil Fumarate (TDF)
    Agarwal, Kosh
    Furusyo, Norihiro
    Byun, Kwan Soo
    Hwang, Jaeseok
    Flaherty, John F.
    Kim, Kyungpil
    Gaggar, Anuj
    Subramanian, Mani
    Jablkowski, Maciej S.
    Yakovlev, Alexey A.
    Trinh, Huy N.
    Buti, Maria
    HEPATOLOGY, 2016, 64 : 910A - 910A
  • [6] Smaller decreases in bone mineral density in chronic hepatitis B patients receiving tenofovir alafenamide compared with tenofovir disoproxil fumarate over 96 weeks
    Fung, S.
    Chuang, W. L.
    Nishiguchi, S.
    Seto, W. K.
    Tak, W. Y.
    Erne, E. M.
    Jablkowski, M.
    Morozov, V.
    Lau, A. H.
    Suri, V.
    Flaherty, J. F.
    Kim, K.
    Gaggar, A.
    Subramanian, G. M.
    Celen, M.
    Lim, S-G
    Chan, H. L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S691 - S692
  • [7] The Impact of Tenofovir Disoproxil Fumarate on Reduced Bone Mineral Density and Fractures in Liver Transplant Recipients
    Lim, N.
    Jackson, S.
    Engler, C.
    Lake, J. R.
    TRANSPLANTATION PROCEEDINGS, 2021, 53 (01) : 215 - 220
  • [8] BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF)
    Buti, Maria
    Gane, Edward J.
    Agarwal, Kosh
    Wong, Grace Lai-Hung C.
    Lim, Young-Suk
    Chen, Chi-Yi
    Lim, Seng Gee
    Yatsuhashi, Hiroshi
    Fung, Scott K.
    Abramov, Frida
    Wang, Hongyuan
    Yee, Leland J.
    Flaherty, John F.
    Pan, Calvin Q.
    Marcellin, Patrick
    HEPATOLOGY, 2023, 78 : S507 - S509
  • [9] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Chan, Henry Lik-Yuen
    Buti, Maria
    Flisiak, Robert
    Ryder, Stephen
    Streinu-Cercel, Adrian
    Flaherty, John F.
    Gaggar, Anuj
    Mo, Shuyuan
    Subramanian, G. Mani
    Zoulim, Fabrian
    Andreone, Pietro
    Marcellin, Patrick
    GUT, 2018, 67 : A97 - A97
  • [10] IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)
    Chan, Henry Lik Yuen
    Lim, Young-Suk
    Seto, Wai Kay
    Ning, Qin
    Agarwal, Kosh
    Janssen, Harry L. A.
    Pan, Calvin O.
    Chuang, Wan Long
    Izumi, Namiki
    Fung, Scott
    Shalimar
    Brunetto, Maurizia
    Flaherty, John
    Mo, Shuyuan
    Cheng, Cong
    Lin, Lanjia
    Gaggar, Anuj
    Subramanian, Mani
    Marcellin, Patrick
    Gane, Edward
    Hou, Jinlin
    Buti, Maria
    GUT, 2020, 69 : A75 - A76
12345